Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.
This study is currently recruiting participants.
Verified by University Hospital, Tours, December 2005
Sponsored by: University Hospital, Tours
Information provided by: University Hospital, Tours
ClinicalTrials.gov Identifier: NCT00263146
  Purpose

Acute Respiratory Distress Syndrom is associated to lung and systemic inflammation, which could be worsened by mechanical ventilation.This included a proteasis - antiproteasis imbalance which could participate to a fibrosis process.

Low tidal-volume ventilation (6 mL/kg) with low plateau pressure (< 30 cm H2O) has been proved to decrease mortality when compared with more conventionnal high-volume (12 mL/kg) ventilation.Moreover, this lung-protective approach decrease lung annd systemic inflammation.

Using recruitment maneuvers (i.e. the application during a short time of high pressures with the intention to re-open the lung, followed by an increase of PEEP-level to keep the lung open, in an attempt to decrease the alveolar shear-stress) has been proposed to improve oxygen and to reduce bio-trauma.

However, the effect of such maneuvers on the inflammatory response and on the evolution of ARDS remains unknown.

Therefore we have planned a randomized, monocentric, controlled trial consisting of the comparison of two approaches of mechanical ventilation in Acute Lung Injury. This trial will include 30 hemodynamically stable patients fulfilling the ALI or ARDS criteria defined by the US and European Consensus Conference.

They will be randomized in two groups: standard low-volume ventilation vs. recruitment maneuvers.

The main objective of our study is to compare both ventilatory strategies in termes of lung and systemic inflammation.

The primary outcome measures will be the proteasis activity as measured in broncho alveolar fluid (BAL) and pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood. Two samples (BAL and blood) will be obtained at a 48-72 hours interval. In the recruitment maneuver group, the first BAL will be obtained two hours before the maneuver.

Secondary outcome measures will be gaz exchange, respiratory mechanics, systemic hemodynamics and visceral dysfunction scores.


Condition Intervention
Acute Lung Injury
Procedure: recruitment maneuver

U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory (ARAMIS: Apport d'Un Recrutement Alveolaire Sur Les Marqueurs De l'Inflammation Dans Le SDRA)

Further study details as provided by University Hospital, Tours:

Primary Outcome Measures:
  • proteasis activity as measured in broncho alveolar fluid (BAL)
  • pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood.

Secondary Outcome Measures:
  • gaz exchange
  • respiratory mechanics
  • systemic hemodynamics
  • visceral dysfunction scores.

Estimated Enrollment: 30
Study Start Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age over 18
  • hospitalization in the ICU
  • under mechanical ventilation
  • Acute Lung Injury (ALI)criteria
  • first week of ALI
  • hemodynamic stability (mAP > 75 mmHg since one hour)
  • informed consent signed (patient or relatives)

Exclusion Criteria:

  • pregnancy
  • obesity (BMI > 40 kg/M2)
  • high probability of D-28 death
  • severe burn injury
  • severe hepatic cirrhosis (Child-Pugh C)
  • aplasia
  • HIV or CHV infection
  • use of more than 0.5 mg/kg of steroïds
  • immunosuppressor agents
  • hemopathy
  • contra indications for BAL
  • contra indications for recruitment maneuvers
  • baro-traumatism
  • left cardiac failure
  • chronic respiratory failure
  • inclusion in another study during the past month
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263146

Contacts
Contact: Gilles Rival, M.D. +33 2 47 47 38 55 rival@med.univ-tours.fr

Locations
France
University Hospital of Tours Recruiting
Tours, France, 37044
Sub-Investigator: Dominique Perrotin, MD            
Sub-Investigator: Annick Legras, MD            
Sub-Investigator: Emmanuelle Mercier, MD            
Sub-Investigator: Denis Garot, MD            
Sub-Investigator: Berengere Narciso, MD            
Sub-Investigator: Guillaume Halley, MD            
Sponsors and Collaborators
University Hospital, Tours
Investigators
Principal Investigator: Gilles Rival, MD University Hospital of Tours
Study Chair: Pierre-Francois Dequin, MD, PhD University Hospital of Tours
Study Director: Francis Gauthier, PhD Inserm U-618
  More Information

Study ID Numbers: ARAMIS
Study First Received: December 5, 2005
Last Updated: December 5, 2005
ClinicalTrials.gov Identifier: NCT00263146  
Health Authority: France: Afssaps - French Health Products Safety Agency

Study placed in the following topic categories:
Respiratory Tract Diseases
Lung Diseases
Respiration Disorders
Respiratory Distress Syndrome, Adult
Acute respiratory distress syndrome
Inflammation

ClinicalTrials.gov processed this record on January 16, 2009